Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 12/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 3/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754467 | 0.95 | PDE1B (0.34) | PDE1BSSTR3KAT8CNR1CNR2 | |
| SCHEMBL26101957 | 0.86 | TYK2 (0.40) | PDE1BSSTR3KAT8CNR1CNR2 | |
| SCHEMBL16794641 | 0.86 | TYK2 (0.40) | PDE1BSSTR3KAT8CNR1CNR2 | |
| SCHEMBL16794640 | 0.86 | TYK2 (0.40) | PDE1BSSTR3KAT8CNR1CNR2 | |
| SCHEMBL16812488 | 0.86 | TYK2 (0.40) | PDE1BSSTR3KAT8CNR1CNR2 | |
| SCHEMBL16794653 | 0.85 | CNR2 (0.41) | CNR1CNR2F10 | |
| SCHEMBL31161333 | 0.85 | SSTR3 (0.35) | PDE1BSSTR3CNR1CNR2F10 | |
| SCHEMBL31161788 | 0.85 | TYK2 (0.37) | PDE1BSSTR3CNR1CNR2F10 | |
| SCHEMBL16794701 | 0.84 | YAP1 (0.41) | PDE1BCNR1CNR2F10 | |
| SCHEMBL16812491 | 0.84 | YAP1 (0.43) | CNR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | TYK2, PTK2B, JAK1 | PDE1B 918/4885SSTR3 3472/4885KAT8 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.